Safety and Efficacy of the Combination Therapy of Fucoidan / Fucoxanthin / L-carnitine in Patients With Diabetic Nephropathy.
The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of The purpose of this open-label, preliminary, proof-of-concept clinical trial is to evaluate the efficacy and safety of fucoidan/fucoxanthin/L-carnitine combinaed therapy in patients with diabetic kidney disease.
Participants were randomly assigned in a 1:1 ratio to either the Treatment Group or the Control Group. The primary objective is to investigate whether fucoidan/fucoxanthin/L-carnitine/Zinc yeast combinaed therapy can significantly improve albuminuria or renal function after a treatment period of 12 weeks. Secondary outcomes include evaluating the safety profile and potential side effects of the intervention.
It is hypothesized that the intervention will show a beneficial effect on albuminuria compared to the control group. in patients withdiabetic kidney disease.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Taipei, Taiwan, 116
- Wanfang Hospital, Taipei Medical Univeristy
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Documented glycated hemoglobin (HbA1c) > 6.5% with current use of anti-diabetic medication.
- A urine albumin-to-creatinine ratio (UACR) greater than 30 mcg/mg.
Exclusion Criteria:
- Age younger than 20 years.
- Inability to understand or provide written informed consent.
- Absence of regular treatment for diabetes mellitus.
- Medication non-compliance, defined as completing less than 50% of the prescribed formula (FFL) treatment.
- Newly diagnosed glomerulonephritis during the study period.
- Loss to follow-up, defined as failure to complete all laboratory tests required for outcome assessment.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: FFL group
Participants received the marine-derived formula FFL (a combination of low-molecular-weight oligo-fucoidan, fucoxanthin-containing extract, and L-carnitine) as an adjunctive therapy to their existing standard-of-care for diabetic kidney disease.
The daily dose consisted of 4 capsules per day, delivering a total of 740 mg of oligo-fucoidan, 1200 mg of fucoxanthin, and 120 mg of L-carnitine.
The intervention was maintained for a total duration of 12 weeks while keeping their baseline anti-diabetic and renoprotective medications unchanged.
|
Combined marine-derived formulation administered orally in capsule form.
Each day, participants took 4 capsules, providing a total daily dose of 740 mg of low-molecular-weight oligo-fucoidan, 1200 mg of fucoxanthin-containing extract, and 120 mg of L-carnitine.
The intervention was used as an add-on therapy to standard diabetic kidney disease care for a total duration of 12 weeks.
|
|
Ingen indgriben: Control group
Participants continued their optimized standard-of-care treatment for diabetic kidney disease (including SGLT2 inhibitors and ACEIs/ARBs) for 12 weeks.
No active capsules or placebos were administered to this group.
All baseline anti-diabetic and blood pressure medications were required to remain stable and unchanged throughout the study period.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR)
Tidsramme: Baseline and Week 12
|
The UACR was assessed via random spot urine collection.
The primary outcome was expressed as the ratio of the difference (end-of-trial value minus baseline value) to the baseline value, calculated using the formula: \((12-weekUACR-BaselineUACR)/BaselineUACR\) * 100%.
A negative percentage indicates a reduction in albuminuria (improvement).
|
Baseline and Week 12
|
|
Percentage Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
Tidsramme: Baseline and Week 12
|
Serum creatinine was measured and eGFR was calculated using the 2021 CKD-EPI creatinine equation.
The outcome was expressed as the ratio of the difference (end-of-trial value minus baseline value) to the baseline value, calculated using the formula: \((12-weekeGFR-BaselineeGFR)/BaselineeGFR\) * 100%.
This parameter was evaluated to monitor for any acute hemodynamically-induced decline (eGFR dip) upon treatment initiation.
|
Baseline and Week 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage Change From Baseline in Glycated Hemoglobin (HbA1c)
Tidsramme: Baseline and Week 12
|
Blood samples were collected to analyze HbA1c levels for evaluating glycemic control.
The outcome was expressed as the ratio of the difference (end-of-trial value minus baseline value) to the baseline value, calculated using the formula: \((12-weekHbA1c-BaselineHbA1c)/BaselineHbA1c\) * 100%.
|
Baseline and Week 12
|
|
Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)
Tidsramme: Baseline and Week 12
|
Fasting lipid profiles were analyzed to evaluate lipid metabolism.
The outcome was expressed as the ratio of the difference (end-of-trial value minus baseline value) to the baseline value, calculated using the formula: \((12-weekLDL-C-BaselineLDL-C)/BaselineLDL-C\) * 100%.
|
Baseline and Week 12
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Chen HH, Sue YM, Chen CH, Hsu YH, Hou CC, Cheng CY, Lin SL, Tsai WL, Chen TW, Chen TH. Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells. Nephrol Dial Transplant. 2009 Oct;24(10):3042-9. doi: 10.1093/ndt/gfp258. Epub 2009 Jun 2.
- Chen YC, Cheng CY, Liu CT, Sue YM, Chen TH, Hsu YH, Hwang PA, Chen CH. Alleviative effect of fucoxanthin-containing extract from brown seaweed Laminaria japonica on renal tubular cell apoptosis through upregulating Na+/H+ exchanger NHE1 in chronic kidney disease mice. J Ethnopharmacol. 2018 Oct 5;224:391-399. doi: 10.1016/j.jep.2018.06.023. Epub 2018 Jun 18.
- Chen TH, Liu CT, Cheng CY, Sue YM, Huang NJ, Chen CH. Oligosaccharides Ameliorate Acute Kidney Injury by Alleviating Cluster of Differentiation 44-Mediated Immune Responses in Renal Tubular Cells. Nutrients. 2022 Feb 11;14(4):760. doi: 10.3390/nu14040760.
- Chen CH, Sue YM, Cheng CY, Chen YC, Liu CT, Hsu YH, Hwang PA, Huang NJ, Chen TH. Oligo-fucoidan prevents renal tubulointerstitial fibrosis by inhibiting the CD44 signal pathway. Sci Rep. 2017 Jan 18;7:40183. doi: 10.1038/srep40183.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Sygdomme i det endokrine system
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Vandladningsforstyrrelser
- Urologiske manifestationer
- Diabetes mellitus
- Diabetes komplikationer
- Proteinuri
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Diabetiske nefropatier
- Albuminuri
- fucoxanthin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- N202409023
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .